Avacta reports early human data for cancer peptide-drug conjugate AVA6103

Avacta reported preliminary human findings for its investigational cancer treatment AVA6103 on September 16, offering an early look at whether a peptide-linked chemotherapy behaves as intended in patients. The company described encouraging safety and drug-exposure observations, but the update does not establish that the treatment shrinks human tumors or improves survival.

The announcement concerns 19 patients enrolled across the first three dose levels of the ongoing FOCUS-01 study. Avacta said the measured pharmacokinetic profile—how drug exposure changes over time—matched its preclinical modeling, with chemotherapy release evident for days after treatment. These are sponsor-reported findings from early development.

What the peptide is designed to do

AVA6103 connects a peptide to exatecan, a chemotherapy payload that inhibits topoisomerase I. The design uses a linker cleaved by fibroblast activation protein, or FAP, which can be expressed by fibroblasts in the tissue surrounding solid tumors.

An earlier Avacta research poster describes the intended mechanism: release the payload within the tumor environment and sustain local exposure while limiting exposure elsewhere. Its supporting experiments included animal tumor models. Those experiments establish a rationale for clinical testing; they cannot determine whether the same balance of activity and toxicity will occur in people.

The peptide's role here is part of an engineered drug-delivery system. Assessing the candidate therefore requires evidence about the complete conjugate: where it travels, where its linker is cleaved, how much active chemotherapy is released and what happens to both tumor and healthy tissue.

What the human study can answer

The publicly available FOCUS-01 registry description identifies a first-in-human, open-label, multicenter Phase 1 study in people with selected locally advanced, unresectable or metastatic solid tumors. It includes dose escalation followed by expansion. Safety assessments include adverse events, while the study also examines pharmacokinetics and initial therapeutic activity.

That design gives researchers a way to investigate tolerability and select exposures for further testing. It does not provide a randomized comparison with an established treatment. Open-label means investigators and participants know which treatment is being administered.

The National Cancer Institute describes Phase 1 cancer trials as small studies focused on safety, side effects and tolerability. Later studies examine activity in larger groups and, in randomized comparisons, help determine whether a new approach performs better than existing care. An early exposure signal occupies only one part of that evidence chain.

Comparisons need careful separation

Avacta also described an animal comparison with Enhertu in a gastric-cancer model. That comparison was preclinical, and the treatments used different schedules. It cannot establish that AVA6103 is more effective than Enhertu in patients.

The company's favorable characterization of early safety likewise needs restraint. A small dose-escalation study cannot reliably characterize uncommon harms or establish comparative safety across different patient populations and treatment schedules. Agreement between observed exposure and a model is useful for development, but is not itself a clinical benefit endpoint.

Avacta expects its first clinical efficacy presentation in the first half of 2027, including tumor-biopsy information. That remains a company forecast. The next consequential evidence will be detailed patient outcomes, adverse-event reporting and follow-up that allows readers to assess how durable any activity is. For now, the update supports continued investigation of the delivery approach without establishing a treatment advantage.